Exelixis Quarterly Balance Sheet
NASDAQ: EXELHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Exelixis financial position
As of Jul 3, 2026, Exelixis reported total assets of $2.49 billion, down 6.9% from a year earlier against total liabilities of $650.5 million. Shareholders' equity stood at $1.84 billion, or 73.9% of assets. The company held $281.4 million in cash and equivalents.
The current ratio (current assets divided by current liabilities) was 3.46, meaning short-term assets cover obligations due within a year.
Summary generated from market data by MetaCap's automated system. Methodology
Exelixis balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-07-03 | Q1 20262026-04-03 | Q4 20252026-01-02 | Q3 20252025-10-03 | Q2 20252025-07-04 | Q1 20252025-04-04 | Q4 20242025-01-03 | Q3 20242024-09-27 | Q2 20242024-06-28 | Q1 20242024-03-29 | Q4 20232023-12-29 | Q3 20232023-09-29 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 281.45M | 226.15M | 482.49M | 376.30M | 164.43M | 183.75M | 217.37M | 258.35M | 198.46M | 259.56M | 262.99M | 396.86M |
| Short-Term Investments | 557.94M | 551.05M | 576.60M | 612.24M | 626.66M | 847.56M | 893.90M | 930.82M | 803.54M | 703.70M | 732.31M | 706.53M |
| Receivables | 322.21M | 328.95M | 286.92M | 309.73M | 292.35M | 281.64M | 265.44M | 269.71M | 396.58M | 240.58M | 237.41M | 248.11M |
| Inventory | 28.73M | 26.61M | 21.69M | 27.40M | 23.48M | 24.85M | 22.39M | 21.01M | 20.61M | 21.11M | 17.32M | 24.98M |
| Total Current Assets | 1.25B | 1.21B | 1.44B | 1.40B | 1.18B | 1.40B | 1.47B | 1.55B | 1.48B | 1.29B | 1.32B | 1.44B |
| Property, Plant & Equipment | 92.67M | 95.52M | 98.96M | 104.75M | 110.31M | 115.03M | 119.39M | 124.41M | 130.21M | 127.22M | 128.73M | 121.04M |
| Goodwill | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M |
| Long-Term Investments | 544.93M | 649.14M | 603.60M | 578.29M | 594.65M | 619.44M | 637.29M | 523.42M | 432.31M | 629.56M | 728.72M | 811.68M |
| Total Assets | 2.49B | 2.59B | 2.84B | 2.82B | 2.68B | 2.84B | 2.95B | 2.96B | 2.77B | 2.80B | 2.94B | 2.98B |
| Accounts Payable | 39.06M | 24.15M | 29.62M | 25.35M | 25.82M | 42.84M | 38.19M | 59.31M | 28.68M | 26.07M | 33.77M | 26.45M |
| Total Current Liabilities | 361.93M | 370.98M | 405.64M | 373.78M | 336.11M | 399.10M | 403.77M | 394.35M | 345.70M | 373.01M | 394.28M | 376.82M |
| Total Liabilities | 650.47M | 657.85M | 683.10M | 662.85M | 644.54M | 706.22M | 703.49M | 684.86M | 653.39M | 675.74M | 678.45M | 629.29M |
| Shareholders' Equity | 1.84B | 1.94B | 2.16B | 2.16B | 2.03B | 2.13B | 2.24B | 2.28B | 2.12B | 2.13B | 2.26B | 2.35B |
| Retained Earnings | -262.53M | -215.79M | -76.83M | -106.06M | -219.54M | -163.29M | -98.65M | -90.29M | -199.97M | -258.95M | -173.35M | -126.05M |
| Net Cash (Debt) | 839.38M | 777.21M | 1.06B | 988.53M | 791.10M | 1.03B | 1.11B | 1.19B | 1.00B | 963.26M | 995.30M | 1.10B |
| Shares Outstanding | 248.88M | 253.70M | 262.48M | 268.10M | 270.13M | 275.03M | 281.73M | 285.78M | 285.22M | 295.03M | 302.79M | 310.97M |
This table shows 12 quarterly periods of Exelixis's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow EXEL's reporting calendar. What is a balance sheet?